Changes in antibody titers against Chlamydia pneumoniae after coronary angioplasty

被引:7
|
作者
Yetkin, G
Yetkin, E [1 ]
Aksoy, Y
Gurbuz, OA
Mert, A
机构
[1] Inonu Univ, Fac Med, Dept Cardiol, Malatya, Turkey
[2] Inonu Univ, Fac Med, Dept Microbiol, Malatya, Turkey
[3] SSK Educ Hosp, Dept Microbiol, Ankara, Turkey
关键词
atheroselerosis; Chlamydia pneumoniae; coronary angioplasty;
D O I
10.1016/j.ijcard.2003.04.045
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The potential role of common infectious agents in the pathogenesis and progression of atherosclerosis has been studied increasingly over the last decade. The evidence for Chlamydia pneumoniae as a potential causative agent is strong and is based on the findings of numerous sero-epidemiological studies, examination of atheromatous plaque specimens, in vitro animal models. We performed a prospective study in percutaneous transluminal coronary angioplasty (PTCA) patients to investigate whether the angioplasty procedure influenced the specific humoral immune response reaction against C. pneumoniae antigens. Methods: We studied 76 patients who successfully underwent PTCA for de novo lesions. Blood samples were drawn immediately before PTCA and 1 month after PTCA. IgG and IgA antibodies against C. pneumoniae (strain CDC/CY&-029) were determined by an in-house developed enzyme inummoassay. Results: At the time of angioplasty 75% and 34% of the patients had seropositive antibodies to elementary bodies (EBs) of classes IgG and IgA, respectively. Mean titers of IgG antibodies before and I month after PTCA were 46 +/- 31 and 50 +/- 28 relative units (RU/ml) (P > 0.05). One month after PTCA, 97% and 34% of the patients had seropositive antibodies to EBs of classes IgG and IgA, respectively. We divided our patients into two groups on the basis of IgG seropositivity (group I: Chlamydia antibody IgG seronegative patients, group II: Chlamydia antibody IgG seropositive) before PTCA. Significant increase in the antibody titers of IgG (12 5 vs. 40 18, P < 0.001) and IgA (0.6 +/- 0.33 vs. 1.15 +/- 0.83, P = 0.007) was observed in group I patients 1 month after PTCA and 88% of them gained IgG seropositivity. There were no significant changes in IgG and IgA antibody levels in group II after PTCA. Conclusion: We have demonstrated a statistically significant rise in C. pneumoniae antibodies (especially IgG) induced by PTCA in patients previously seronegative. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:293 / 297
页数:5
相关论文
共 50 条
  • [31] Detection of Chlamydophila pneumoniae (Chlamydia pneumoniae) in endarteroctomy specimens of coronary heart diseases patients
    Satpathy, Gita
    Bhan, Anil
    Sharma, Anjana
    Kar, U. K.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2008, 128 (05) : 658 - 662
  • [32] Chlamydia pneumoniae and future risk in patients with coronary heart disease
    Haim, M
    Tanne, D
    Battler, A
    Boyko, V
    Reshef, T
    Goldbourt, U
    Brunner, D
    Mekori, YA
    Behar, S
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2004, 93 (01) : 25 - 30
  • [33] RESTENOSIS AFTER CORONARY ANGIOPLASTY
    HAMON, M
    BAUTERS, C
    MCFADDEN, EP
    WERNERT, N
    LABLANCHE, JM
    DUPUIS, B
    BERTRAND, ME
    EUROPEAN HEART JOURNAL, 1995, 16 : 33 - 48
  • [34] Evidence for persistent Chlamydia pneumoniae infection of human coronary atheromas
    Borel, Nicole
    Summersgill, James T.
    Mukhopadhyay, Sanghamitra
    Miller, Richard D.
    Ramirez, Julio A.
    Pospischil, Andreas
    ATHEROSCLEROSIS, 2008, 199 (01) : 154 - 161
  • [35] The adventitia of atherosclerotic coronary arteries frequently contains Chlamydia pneumoniae
    Vink, A
    Pasterkamp, G
    Poppen, M
    Schoneveld, AH
    de Kleijn, DPV
    Roholl, PJM
    Fontijn, J
    Plomp, S
    Borst, C
    ATHEROSCLEROSIS, 2001, 157 (01) : 117 - 122
  • [36] Circulating Chlamydia pneumoniae DNA and advanced coronary artery disease
    Wang, Shaoshan S.
    Tondella, Maria Lucia C.
    Bajpai, Ambar
    Mathew, Anil G.
    Mehranpour, Payam
    Li, Wei
    Kacharava, Andro G.
    Fields, Barry S.
    Austin, Harland
    Zafari, A. Maziar
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 118 (02) : 215 - 219
  • [37] In Vitro Activity of Nafithromycin (WCK 4873) against Chlamydia pneumoniae
    Kohlhoff, Stephan
    Hammerschlag, Margaret R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (09)
  • [38] In Vitro Activity of Levonadifloxacin (WCK 771) against Chlamydia pneumoniae
    Kohlhoff, Stephan
    Huerta, Natalia
    Hammerschlag, Margaret R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (08)
  • [39] Association of Chlamydia pneumoniae antibody with the cholesterol-lowering effect of statins
    Sawayama, Y
    Tatsukawa, M
    Okada, K
    Maeda, N
    Shimizu, C
    Kikuchi, K
    Hayashi, J
    ATHEROSCLEROSIS, 2003, 171 (02) : 281 - 285
  • [40] Antibodies against Chlamydia pneumoniae and their relation to lymphocyte population levels
    González-Castañeda, C
    Pérez-Castrillón, JL
    Romero-Gómez, M
    Herreros-Fernández, V
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 82 (03) : 293 - 295